Literature DB >> 21106306

American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer.

Seth A Rosenthal1, Nathan H J Bittner, David C Beyer, D Jeffrey Demanes, Brian J Goldsmith, Eric M Horwitz, Geoffrey S Ibbott, W Robert Lee, Subir Nag, W Warren Suh, Louis Potters.   

Abstract

Transperineal permanent prostate brachytherapy is a safe and efficacious treatment option for patients with organ-confined prostate cancer. Careful adherence to established brachytherapy standards has been shown to improve the likelihood of procedural success and reduce the incidence of treatment-related morbidity. A collaborative effort of the American College of Radiology (ACR) and American Society for Therapeutic Radiation Oncology (ASTRO) has produced a practice guideline for permanent prostate brachytherapy. The guideline defines the qualifications and responsibilities of all the involved personnel, including the radiation oncologist, physicist and dosimetrist. Factors with respect to patient selection and appropriate use of supplemental treatment modalities such as external beam radiation and androgen suppression therapy are discussed. Logistics with respect to the brachytherapy implant procedure, the importance of dosimetric parameters, and attention to radiation safety procedures and documentation are presented. Adherence to these practice guidelines can be part of ensuring quality and safety in a successful prostate brachytherapy program. Copyright Â
© 2011 American Society for Radiation Oncology and American College of Radiology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21106306     DOI: 10.1016/j.ijrobp.2010.08.045

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  19 in total

1.  Radiobiological effect induced by different activities of (125)I seed brachytherapy in a hepatocellular carcinoma model.

Authors:  Qing-Hong Qin; Bai-Sha Huang; Qi-Xing Tan; Wei-Ping Yang; Bin Lian; Chang-Yuan Wei
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Seed loss in prostate brachytherapy : Operator dependency and impact on dosimetry.

Authors:  Nancy El-Bared; Natanel Sebbag; Dominic Béliveau-Nadeau; Yannick Hervieux; Renée Larouche; Daniel Taussky; Guila Delouya
Journal:  Strahlenther Onkol       Date:  2016-02-29       Impact factor: 3.621

3.  Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS).

Authors:  Shiro Saito; Kazuto Ito; Atsunori Yorozu; Manabu Aoki; Hirofumi Koga; Takefumi Satoh; Toshio Ohashi; Naoyuki Shigematsu; Shinichiro Maruo; Takashi Kikuchi; Shinsuke Kojima; Takushi Dokiya; Masanori Fukushima; Hidetoshi Yamanaka
Journal:  Int J Clin Oncol       Date:  2014-05-21       Impact factor: 3.402

4.  Impact of learning curve and technical changes on dosimetry in low-dose brachytherapy for prostate cancer.

Authors:  E Le Fur; J P Malhaire; D Baverez; F Delage; M A Perrouin-Verbe; F Schlurmann; S Guerif; G Fournier; O Pradier; A Valeri
Journal:  Strahlenther Onkol       Date:  2012-11-11       Impact factor: 3.621

5.  Statin use is associated with decreased prostate cancer recurrence in men treated with brachytherapy.

Authors:  Daniel S Oh; Bridget Koontz; Stephen J Freedland; Leah Gerber; Pretesh Patel; Stephen Lewis; David S Yoo; James Oleson; Joseph K Salama
Journal:  World J Urol       Date:  2014-03-27       Impact factor: 4.226

6.  Permanent interstitial low-dose-rate brachytherapy for patients with low risk prostate cancer: An interim analysis of 312 cases.

Authors:  Harun Badakhshi; Reinhold Graf; Volker Budach; Peter Wust
Journal:  Strahlenther Onkol       Date:  2014-10-23       Impact factor: 3.621

7.  Is it necessary to perform week three dosimetric analysis in low-dose-rate brachytherapy for prostate cancer when day 0 dosimetry is done? A quality assurance assessment.

Authors:  T Shaikh; N G Zaorsky; K Ruth; D Y Chen; R E Greenberg; J Li; K Crawford; E M Horwitz
Journal:  Brachytherapy       Date:  2014-11-07       Impact factor: 2.362

8.  Comparing CTVs for permanent prostate brachytherapy.

Authors:  C A Oton; L Blanco; L F Oton; S Moral
Journal:  Clin Transl Oncol       Date:  2014-10-29       Impact factor: 3.405

9.  Feasibility of transrectal ultrasonography for assessment of cervical cancer.

Authors:  M P Schmid; R Pötter; P Brader; A Kratochwil; G Goldner; K Kirchheiner; A Sturdza; C Kirisits
Journal:  Strahlenther Onkol       Date:  2012-12-21       Impact factor: 3.621

10.  Preoperative treatment planning with intraoperative optimization can achieve consistent high-quality implants in prostate brachytherapy.

Authors:  Rajat J Kudchadker; Thomas J Pugh; David A Swanson; Teresa L Bruno; Yasemin Bolukbasi; Steven J Frank
Journal:  Med Dosim       Date:  2012-05-03       Impact factor: 1.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.